Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| fibroblast | 41 studies | 44% ± 22% | |
| endothelial cell | 24 studies | 44% ± 20% | |
| endothelial cell of lymphatic vessel | 22 studies | 57% ± 24% | |
| smooth muscle cell | 17 studies | 28% ± 14% | |
| endothelial cell of vascular tree | 13 studies | 42% ± 18% | |
| vein endothelial cell | 12 studies | 47% ± 22% | |
| pericyte | 11 studies | 38% ± 17% | |
| connective tissue cell | 10 studies | 47% ± 15% | |
| adipocyte | 10 studies | 43% ± 11% | |
| endothelial cell of artery | 9 studies | 38% ± 14% | |
| type II pneumocyte | 8 studies | 36% ± 14% | |
| mesothelial cell | 8 studies | 45% ± 28% | |
| myofibroblast cell | 7 studies | 42% ± 19% | |
| hepatocyte | 6 studies | 65% ± 29% | |
| adventitial cell | 5 studies | 72% ± 20% | |
| basal cell | 4 studies | 38% ± 20% | |
| capillary endothelial cell | 4 studies | 32% ± 19% | |
| hepatic stellate cell | 3 studies | 44% ± 19% | |
| abnormal cell | 3 studies | 56% ± 26% | |
| glial cell | 3 studies | 43% ± 22% | |
| epithelial cell | 3 studies | 61% ± 31% | |
| luminal hormone-sensing cell of mammary gland | 3 studies | 22% ± 4% | |
| endothelial cell of sinusoid | 3 studies | 27% ± 10% | |
| muscle cell | 3 studies | 47% ± 15% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| breast | 98% | 20281.96 | 449 / 459 | 87% | 124.67 | 970 / 1118 |
| lung | 95% | 12130.69 | 551 / 578 | 82% | 143.23 | 951 / 1155 |
| liver | 97% | 60740.88 | 219 / 226 | 75% | 424.73 | 306 / 406 |
| skin | 83% | 14736.75 | 1493 / 1809 | 57% | 82.36 | 269 / 472 |
| kidney | 52% | 5204.29 | 46 / 89 | 85% | 717.85 | 767 / 901 |
| bladder | 67% | 8877.95 | 14 / 21 | 53% | 96.41 | 266 / 504 |
| uterus | 65% | 5029.36 | 111 / 170 | 54% | 115.70 | 248 / 459 |
| intestine | 66% | 5779.03 | 642 / 966 | 41% | 53.43 | 214 / 527 |
| pancreas | 14% | 655.63 | 45 / 328 | 92% | 291.94 | 163 / 178 |
| adipose | 100% | 25000.50 | 1203 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 25745.14 | 1332 / 1335 | 0% | 0 | 0 / 0 |
| ovary | 38% | 2337.13 | 69 / 180 | 60% | 94.02 | 257 / 430 |
| esophagus | 54% | 4131.24 | 787 / 1445 | 42% | 44.33 | 77 / 183 |
| thymus | 77% | 6346.49 | 504 / 653 | 19% | 16.48 | 117 / 605 |
| stomach | 46% | 4461.81 | 165 / 359 | 48% | 49.41 | 137 / 286 |
| spleen | 89% | 6474.22 | 215 / 241 | 0% | 0 | 0 / 0 |
| prostate | 51% | 4322.06 | 124 / 245 | 31% | 27.83 | 158 / 502 |
| muscle | 67% | 13936.64 | 542 / 803 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 55% | 71.28 | 16 / 29 |
| heart | 45% | 3068.41 | 385 / 861 | 0% | 0 | 0 / 0 |
| adrenal gland | 22% | 998.19 | 57 / 258 | 11% | 19.33 | 26 / 230 |
| tonsil | 0% | 0 | 0 / 0 | 31% | 28.50 | 14 / 45 |
| brain | 0% | 4.39 | 3 / 2642 | 22% | 49.41 | 152 / 705 |
| peripheral blood | 1% | 137.10 | 13 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0090312 | Biological process | positive regulation of protein deacetylation |
| GO_0045722 | Biological process | positive regulation of gluconeogenesis |
| GO_0006769 | Biological process | nicotinamide metabolic process |
| GO_0009410 | Biological process | response to xenobiotic stimulus |
| GO_0031100 | Biological process | animal organ regeneration |
| GO_0032259 | Biological process | methylation |
| GO_0034356 | Biological process | NAD biosynthesis via nicotinamide riboside salvage pathway |
| GO_0010243 | Biological process | response to organonitrogen compound |
| GO_0005829 | Cellular component | cytosol |
| GO_0030760 | Molecular function | pyridine N-methyltransferase activity |
| GO_0008112 | Molecular function | nicotinamide N-methyltransferase activity |
| Gene name | NNMT |
| Protein name | NNMT protein (Nicotinamide N-methyltransferase) Nicotinamide N-methyltransferase (EC 2.1.1.1) |
| Synonyms | hCG_39357 |
| Description | FUNCTION: Catalyzes the N-methylation of nicotinamide using the universal methyl donor S-adenosyl-L-methionine to form N1-methylnicotinamide and S-adenosyl-L-homocysteine, a predominant nicotinamide/vitamin B3 clearance pathway . Plays a central role in regulating cellular methylation potential, by consuming S-adenosyl-L-methionine and limiting its availability for other methyltransferases. Actively mediates genome-wide epigenetic and transcriptional changes through hypomethylation of repressive chromatin marks, such as H3K27me3 . In a developmental context, contributes to low levels of the repressive histone marks that characterize pluripotent embryonic stem cell pre-implantation state . Acts as a metabolic regulator primarily on white adipose tissue energy expenditure as well as hepatic gluconeogenesis and cholesterol biosynthesis. In white adipocytes, regulates polyamine flux by consuming S-adenosyl-L-methionine which provides for propylamine group in polyamine biosynthesis, whereas by consuming nicotinamide controls NAD(+) levels through the salvage pathway (By similarity). Via its product N1-methylnicotinamide regulates protein acetylation in hepatocytes, by repressing the ubiquitination and increasing the stability of SIRT1 deacetylase (By similarity). Can also N-methylate other pyridines structurally related to nicotinamide and play a role in xenobiotic detoxification . . |
| Accessions | P40261 ENST00000535401.5 ENST00000299964.4 B0YJ53 |